Ftse Mib
37.133,04
0,21%
DAX
21.803,65
0,19%
S&P 500
6.025,99
-0,95%
NASDAQ
19.523,40
-1,36%
Bitcoin
97.794,32
1,35%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Akero Therapeutics Inc (AKRO) Akero Therapeutics Inc (AKRO) Notizie

AKRO

Akero Therapeutics (AKRO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AKRO
DataOraFonteTitoloSimboloCompagnia
08/02/202501:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
30/01/202522:05GlobeNewswire Inc.Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:AKROAkero Therapeutics Inc
30/01/202513:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKROAkero Therapeutics Inc
29/01/202523:08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AKROAkero Therapeutics Inc
29/01/202503:30GlobeNewswire Inc.Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:AKROAkero Therapeutics Inc
28/01/202503:35Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:AKROAkero Therapeutics Inc
27/01/202522:24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKROAkero Therapeutics Inc
27/01/202522:01GlobeNewswire Inc.Akero Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:AKROAkero Therapeutics Inc
27/01/202512:30GlobeNewswire Inc.Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY StudyNASDAQ:AKROAkero Therapeutics Inc
24/01/202522:05GlobeNewswire Inc.Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASHNASDAQ:AKROAkero Therapeutics Inc
24/01/202517:01PR Newswire (US)Kuehn Law Encourages Investors of Akero Therapeutics, Inc. to Contact Law FirmNASDAQ:AKROAkero Therapeutics Inc
13/01/202513:00GlobeNewswire Inc.Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLDNASDAQ:AKROAkero Therapeutics Inc
07/01/202513:00GlobeNewswire Inc.Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AKROAkero Therapeutics Inc
26/11/202413:00GlobeNewswire Inc.Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:AKROAkero Therapeutics Inc
15/11/202417:00GlobeNewswire Inc.Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024NASDAQ:AKROAkero Therapeutics Inc
13/11/202422:05GlobeNewswire Inc.Akero Therapeutics to Present at the Jefferies London Healthcare ConferenceNASDAQ:AKROAkero Therapeutics Inc
08/11/202413:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AKROAkero Therapeutics Inc
08/11/202413:00GlobeNewswire Inc.Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AKROAkero Therapeutics Inc
21/10/202413:00GlobeNewswire Inc.Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024NASDAQ:AKROAkero Therapeutics Inc
01/10/202403:37PR Newswire (US)INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law FirmNASDAQ:AKROAkero Therapeutics Inc
30/09/202413:00GlobeNewswire Inc.Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual ConferenceNASDAQ:AKROAkero Therapeutics Inc
09/09/202413:00GlobeNewswire Inc.Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASHNASDAQ:AKROAkero Therapeutics Inc
28/08/202422:05GlobeNewswire Inc.Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:AKROAkero Therapeutics Inc
09/08/202413:00GlobeNewswire Inc.Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AKROAkero Therapeutics Inc
11/06/202413:00GlobeNewswire Inc.Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASHNASDAQ:AKROAkero Therapeutics Inc
08/06/202414:15GlobeNewswire Inc.Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024NASDAQ:AKROAkero Therapeutics Inc
29/05/202413:00GlobeNewswire Inc.Akero Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:AKROAkero Therapeutics Inc
10/05/202422:57Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:AKROAkero Therapeutics Inc
10/05/202413:00GlobeNewswire Inc.Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AKROAkero Therapeutics Inc
08/05/202413:00GlobeNewswire Inc.Akero Therapeutics to Present at the BofA Securities 2024 Health Care ConferenceNASDAQ:AKROAkero Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AKRO

La tua Cronologia

BIT
UCG
Unicredit
BIT
BPE
Bper Banca
BIT
TIT
Telecom Italia
BIT
IVG
Iveco Group NV
BIT
ISP
Intesa Sanpaolo
BIT
BAMI
Banco BPM
BIT
BPSO
Banca Popolare di Sondrio
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
RACE
Ferrari NV
BIT
TITR
Telecom Italia
BIT
TEN
Tenaris
BIT
STMMI
ST Microelectronics
BIT
G
Generali
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci